Tech

Weight-loss drugs show signs of slowing biological aging, say drugmakers

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/10/2026, 17:20:24 UTC.

Briefings

Drugmakers Eli Lilly and Novo Nordisk reported that GLP-1 weight-loss medications, including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), slow biological aging by reducing molecular clocks. Novo found a 2-3 year reduction in biological age across trials, while Lilly observed a 4-year slowdown in heart protein clocks. These findings suggest GLP-1 drugs may act as geroprotectors, extending healthspan and potentially lifespan. The research involved 10,052 Novo participants and smaller Lilly studies, with findings presented at the Aging Research & Drug Discovery conference in October 2026.

Key points

• Novo Nordisk's semaglutide (Ozempic and Wegovy) reduced biological age by approximately two to three years in overweight and diabetic patients compared to placebo, measured via proteomic clocks.
• Eli Lilly's tirzepatide (Mounjaro and Zepbound) slowed molecular aging clocks by up to four years in heart protein measurements, with consistent reductions observed across multiple drug types.

Context and limitations

Findings are based on clinical trials and conference presentations; real-world effects in healthy populations remain uncertain. Side effects like muscle loss are noted, and long-term lifespan impacts are not yet confirmed.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 06/10/2026, 17:28:26 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidi52iziiksf3az5lafnktw7ho5q5pgaescjcvznnhvior3cxrry4